


AMENDMENTS



In the Claims

Please enter the following amendments:


1. (currently amended) A pharmaceutical or veterinary composition, comprising a carrier or diluent, a dehydroepiandrosterone, or pharmaceutically or veterinarianily acceptable salts thereof, the dehydroepiandrosterone having the chemical formula




wherein the broken line represents a single or a double bond; R is hydrogen or a halogen; the H at position 5 is present in the alpha or beta configuration or the compound of chemical formula I comprises a racemic mixture of both configurations; and R¹ is hydrogen or SO₂OM, where M is selected from H, Na, sulfatide



wherein R² and R³, which may be the same or different, are straight or branched (C₁-C₁₄)



alkyl or glucuronide; and a ubiquinone or pharmaceutically or veterinarianily acceptable salt thereof, wherein the ubiquinone has the chemical formula



wherein n is 1 to 12, the agent being present in an amount effective for altering levels of, or sensitivity to, adenosine or adenosine receptors, adenosine in a subject's tissue (s), or treating bronchoconstriction, lung inflammation or allergies, chronic obstructive pulmonary disease (COPD) or a disease associated with either of them, wherein said pharmaceutical or veterinary composition is an inhalable, respirable, or intrapulmonary formulation.

2. (previously presented) The composition of claim 1, wherein in the CoQ_n of formula II, wherein n is 1 to 10.

3. (previously presented) The composition of claim 1, wherein the CoQ_n of formula II, wherein n is 6 to 10.

4. (previously presented) The composition of claim 3, wherein in the CoQ_n of formula II, wherein n is 10.

5. (previously presented) The composition of claim 4, comprising about 0.1 to about 49% w/w dehydroepiandrosterone, or pharmaceutically or veterinarily acceptable salt thereof, or a ubiquinone or pharmaceutically or veterinarily acceptable salt thereof.

6. (previously presented) The composition of claim 5, comprising about 1 to about 20% w/w dehydroepiandrosterone, or pharmaceutically or veterinarily acceptable salt thereof, or a ubiquinone or pharmaceutically or veterinarily acceptable salt thereof.

7. (previously presented) The composition of claim 1, wherein the compound of formula (I) is dehydroepiandrosterone, where R and R¹ are each hydrogen and the broken line represents a double bond.

8. (previously presented) The composition of claim 1, wherein the compound of formula (I) is 16-alpha bromoepiandrosterone, where R is Br, and R¹ is H, and the broken line represents a double bond.

9. (previously presented) The composition of claim 1, wherein the compound of formula (I) is 16-alpha-fluoro epiandrosterone, wherein R is F, R¹ is H, and the broken line

represents a double bond.

10. (previously presented) The composition of claim 1, wherein the compound of formula (I) is etiocholanolone, wherein R and R¹ are each hydrogen and the broken line represents a double bond.

11. (previously presented) The composition of claim 1, wherein the compound of formula (I) is dehydroepiandrosterone sulfate, wherein R is H, R¹ is SO₂OM, and M is a sulfatide group as defined above, and the broken line represents a single bond.

12. (previously presented) The composition of claim 1, wherein the compound of formula (I), R is halogen selected from Br, Cl or F, R¹ is H, and the broken line represents a double bond.

13. (previously presented) The composition of claim 1, wherein the compound of formula (I) is 16-alpha-fluoro epiandrosterone.

14. (previously presented) The composition of claim 1, wherein the compound of formula (I) is selected from dehydroepiandrosterone, 16-alpha-bromoepiandrosterone, 16-alpha-fluoro epiandrosterone, etiocholanolone, dehydroepiandrosterone sulfate or pharmaceutically or veterinarianily acceptable salts thereof.

15. (previously presented) The composition of claim 1, wherein the carrier or diluent comprises a pharmaceutically or veterinarianily acceptable carrier or diluent.

16. (canceled).

17. (previously presented) The composition of claim 15, further comprising a folinic acid, a pharmaceutically or veterinarianily acceptable salts of folinic acid, a preservatives, a antioxidants, a flavoring agents, a volatile oils, a buffering agents, a dispersants or a surfactants.

18. (currently amended) The composition of claim 15, which is a systemic or topical formulation.

19. (canceled).

20. (canceled).

21. (canceled).

22. (canceled).

23. (canceled).

24. (canceled).

25. (canceled).
26. (canceled).
27. (canceled).
28. (canceled).
29. (previously presented) The composition of claim 1 in bulk or in single or multi-dose form.
30. (previously presented) The composition of claim 29, wherein the single or multi-dose forms is provided in sealed ampoules or vials.
31. (previously presented) The composition of claim 1, which is freeze-dried or lyophilized.
32. (canceled).
33. (canceled).
34. (canceled).
35. (canceled).
36. (currently amended) The composition of claim ~~35~~ 1, wherein said composition is an aerosol ~~or spray~~ comprising liquid or solid particles of the active agent, and which further comprises an ingredient selected from folinic acid, other therapeutic agents, preservatives, antioxidants, flavoring agents, volatile oils, buffering agents, dispersants or surfactants.
37. (previously presented) The composition of claim 36, comprising an inhalable or respirable formulation comprising powdered or liquid particles of the active agent about 0.05 to about 10 μ in size.
38. (previously presented) The composition of claim 37, comprising an inhalable or respirable aerosol formulation comprising powdered or liquid particles of the active agent about 0.1 to about 5 μ in size.
39. (currently amended) The composition of claim 36, which comprises a ~~nasal~~ or intrapulmonary aerosol formulation comprising powdered or liquid particles of the active agent about 10 to about 100 μ in size.
40. (previously presented) The composition of claim 39, which comprises powdered or liquid particles of the active agent about 10 to about 50 μ in size.
41. (previously presented) The composition of claim 15, wherein the carrier

comprises a hydrophobic carrier.

42. (previously presented) A kit comprising the composition of claim 15, and a delivery device.

43. (currently amended) The kit of claim 42, wherein ~~the composition comprises an inhalable, respirable, intrapulmonary or nasal formulation, and the delivery device comprises an inhaler provided with an aerosol generating means.~~

44. (previously presented) The kit of claim 42, wherein the delivery device delivers individual pre-metered doses of the composition.

45. (previously presented) The kit of claim 42, wherein the delivery device comprises an inhaler.

46. (previously presented) The kit of claim 42, wherein the inhaler comprises a nebulizer or insufflator.

47. (previously presented) The kit of claim 42, wherein the delivery device comprises a compression inhaler, and the composition comprises a suspension or solution in an aqueous or non-aqueous liquid or an oil-in-water or water-in-oil emulsion.

48. (previously presented) The kit of claim 41, wherein the composition is provided in a pierceable or openable capsule or cartridge.

Claims 49-79 (canceled).